The FDA has determined that the supply of Eli Lilly's Zepbound and Mounjaro meets or exceeds current demand, leading to the decision to phase out off-brand versions.
With the overwhelming demand for GLP-1 drugs, compounding pharmacies and telehealth companies had begun selling cheaper alternatives. However, safety concerns prompted the FDA's intervention.
Collection
[
|
...
]